Clinical Trials Logo

Immune Checkpoint Inhibition clinical trials

View clinical trials related to Immune Checkpoint Inhibition.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03610711 Active, not recruiting - Clinical trials for Gastroesophageal Cancer

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

REACTION
Start date: March 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).